The Conversation (0)
Life Science Big News Roundup: Biocure Enters into Exclusive Joint R&D Agreement with Pharos Vaccine Inc.; Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell; Lexaria’s DehydraTECHTM Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations
May. 17, 2019 10:00AM PST
Life Science Investing News
In case you missed it, here is this week’s life science big news roundup.
In case you missed it, here is this week’s life science big news roundup:
Biotech:
- Biocure Enters into Exclusive Joint R&D Agreement with Pharos Vaccine Inc. for Overseas Market of CAR T-Cell Products
- Lexaria’s DehydraTECHTM Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations
- Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell Therapeutics Corp.
To see our previous Life Science Investing Big News Roundups, please click here.